These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 7485806)

  • 61. [New local therapy of atrophic vaginitis].
    Lieveaux A
    Gynecol Prat; 1972; 23(4):193-5. PubMed ID: 4197031
    [No Abstract]   [Full Text] [Related]  

  • 62. Low-dose intravaginal estradiol delivery using a Silastic vaginal ring for estrogen replacement therapy in postmenopausal women: a review.
    Sarkar NN
    Eur J Contracept Reprod Health Care; 2003 Dec; 8(4):217-24. PubMed ID: 15006269
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Randomized, multicenter, double-blind, placebo-controlled trial to evaluate the efficacy and safety of synthetic conjugated estrogens B for the treatment of vulvovaginal atrophy in healthy postmenopausal women.
    Simon JA; Reape KZ; Wininger S; Hait H
    Fertil Steril; 2008 Oct; 90(4):1132-8. PubMed ID: 18053998
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Continuous, low dosage estradiol administration with a vaginal ring: a placebo-controlled study].
    Casper F; Petri E; Benninghoff B
    Zentralbl Gynakol; 1998; 120(9):449-53. PubMed ID: 9796090
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Transvaginal dehydroepiandrosterone: an unconventional proposal to deliver a mysterious androgen that has no receptor or target tissue using a strategy with a new name: hormone precursor replacement therapy (HPRT).
    Buster JE
    Menopause; 2009; 16(5):858-9. PubMed ID: 19574935
    [No Abstract]   [Full Text] [Related]  

  • 66. Intravaginal oestrogen and progestin administration: advantages and disadvantages.
    Cicinelli E
    Best Pract Res Clin Obstet Gynaecol; 2008 Apr; 22(2):391-405. PubMed ID: 17981510
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Uterine and vaginal effects of unopposed ultralow-dose transdermal estradiol.
    Johnson SR; Ettinger B; Macer JL; Ensrud KE; Quan J; Grady D
    Obstet Gynecol; 2005 Apr; 105(4):779-87. PubMed ID: 15802405
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Effective treatment of vaginal atrophy with an ultra-low-dose estradiol vaginal tablet.
    Simon J; Nachtigall L; Gut R; Lang E; Archer DF; Utian W
    Obstet Gynecol; 2008 Nov; 112(5):1053-60. PubMed ID: 18978105
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Vulvovaginal complaints.
    Mehta A; Bachmann G
    Clin Obstet Gynecol; 2008 Sep; 51(3):549-55. PubMed ID: 18677149
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Transdermal estradiol--the possibility for replacement therapy in the postmenopause].
    Rachev E
    Akush Ginekol (Sofiia); 1994; 33(3):45-7. PubMed ID: 7793531
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Topical estrogen therapy in the management of postmenopausal vaginal atrophy: an up-to-date overview.
    Al-Baghdadi O; Ewies AA
    Climacteric; 2009 Apr; 12(2):91-105. PubMed ID: 19117185
    [TBL] [Abstract][Full Text] [Related]  

  • 72. By the way, doctor. My gynecologist says that I have atrophic vaginitis and that it's a common problem for menopausal women. In all my reading about menopause, I've never come across this condition. What can you tell me about it?
    Harv Womens Health Watch; 2002 Feb; 9(6):7. PubMed ID: 14521132
    [No Abstract]   [Full Text] [Related]  

  • 73. Vulvovaginal atrophy: new and upcoming approaches.
    Simon JA
    Menopause; 2009; 16(1):5-7. PubMed ID: 19131842
    [No Abstract]   [Full Text] [Related]  

  • 74. Pharmacokinetic data on estradiol in light of the estring concept. Estradiol and estring pharmacokinetics.
    Gabrielsson J; Wallenbeck I; Birgerson L
    Acta Obstet Gynecol Scand Suppl; 1996; 163():26-31; discussion 32-4. PubMed ID: 8916472
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Vulvovaginal Atrophy.
    Kellogg-Spadt S
    Adv Nurse Pract; 2010 Apr; 18(4):31-32, 34, 55. PubMed ID: 20486301
    [No Abstract]   [Full Text] [Related]  

  • 76. [Therapy in estrogen deficiency of the vagina].
    Zsolnai B; Király F
    Zentralbl Gynakol; 1982; 104(21):1374-8. PubMed ID: 7164642
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [Therapeutic trial of the combination promestriene-chlorquinaldol in the treatment of vaginitis].
    Senèze J; Duthion P
    Rev Fr Gynecol Obstet; 1985 Apr; 80(5):323-5. PubMed ID: 4023539
    [No Abstract]   [Full Text] [Related]  

  • 78. [The treatment of severe and recurrent nonspecific colpitis].
    Dörffler P
    Fortschr Med; 1978 Jan; 96(1):35-8. PubMed ID: 202550
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Vulvovaginal atrophy: a common--and commonly overlooked--problem.
    Hohenhaus MH
    Med Health R I; 2011 May; 94(5):138-40. PubMed ID: 21710922
    [No Abstract]   [Full Text] [Related]  

  • 80. [Methyl-partricin and vaginitis. Further controlled clinical research].
    Tarnóczi P
    Minerva Ginecol; 1976; 28(7-8):643-8. PubMed ID: 1037113
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.